Home | About | Events | Contact | Advisory Board | Writer’s Guidelines | Reprints | Organizations | Advertising
Translational Sciences Corporation to Launch OncoTrac™ at the American Society of Clinical Oncology (ASCO) Annual MeetingNew Medical Software Can Provide Untapped Information to Benefit Cancer Researchers BOSTON and CHICAGO, June 1, 2011 /PRNewswire/ -- Translational Sciences Corp. (TSC) will launch OncoTrac™ for Clinical Research at the America Society of Clinical Oncology (ASCO), June 4-6, at Chicago's McCormick Place, Booth #22114. The OncoTrac™ family of software products provides a structured workflow solution for clinicians to report precise measurement of solid and metastatic tumor progression. OncoTrac™ for Clinical Research enterprise software facilitates tumor response assessment using widely accepted standards such as RECIST 1.0, RECIST 1.1, and WHO, as well as emerging standards such as the Choi criteria. Assessments using these criteria are commonly required by clinical trial protocols and are often submitted as primary and secondary end-point data in new anti-cancer FDA drug approval applications. Yet, not all clinical cancer research reports tumor response correctly with regard to these standards. OncoTrac™is designed to assure conformity to these standards and aid compliance with established clinical research standards including FDA Good Clinical Practice (GCP) and Part 11 Electronic Medical Records. Subject assessment data are integrated into existing research workflows, thereby providing capabilities comparable to those performed at core imaging laboratories in support of drug applications. Medical imaging techniques such as CT and MRI produce very large data sets that are typically displayed as images and read by clinicians. Often times, subtle but clinically significant findings can be difficult to visualize and computational analysis has been demonstrated to assist precise identification or measurement of disease. The routine implementation of RECIST as a research standard is a clear example,” said Howard Pinsky, CEO of Translational Sciences Corp. “Recently, the Radiological Society of North America (RSNA), the world’s largest professional radiology society, has made a significant commitment to the integration of quantitative imaging into radiology practice -- an ambitious goal requiring development and deployment of dedicated software like OncoTrac™.” ABOUT TRANSLATIONAL SCIENCES Headquartered in Cambridge, Massachusetts, Translational Sciences Corp. (TSC) is a medical software company dedicated to adding value to medical imaging studies, increasing physician efficiency, and improving patient management. Contact:Anthony Grise |
